

# GILEAD SCIENCES INC.

ISIN: US3755581036 WKN: 375558103 Asset Class: Stock

## Company

2024/05/10 22:00:00



Price  
**65.96**  
USD

Difference ▲  
2.14%(1.38)



## Contact Details

GILEAD SCIENCES INC. Tel: +1-650-574-3000  
 -- Fax: +1-650-522-5853  
 333 Lakeside Drive Web: <http://www.gilead.com>  
 94404 Foster City E-mail: -

## Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2023           |                        | 2022           |                        | 2021           |                        |
|---------------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
|                                       | Assets         | Liabilities and equity | Assets         | Liabilities and equity | Assets         | Liabilities and equity |
| <b>Current assets</b>                 | 16,085,000,000 |                        | 14,443,000,000 |                        | 14,772,000,000 |                        |
| <b>Common stock capital</b>           |                | 1,000,000              |                | 1,000,000              |                | 1,000,000              |
| <b>Fixed assets</b>                   | 46,040,000,000 |                        | 48,728,000,000 |                        | 53,180,000,000 |                        |
| <b>Equity capital of a company</b>    |                | 22,749,000,000         |                | 21,209,000,000         |                | 21,064,000,000         |
| <b>Cash and cash equivalents</b>      | 6,085,000,000  |                        | 5,412,000,000  |                        | 5,338,000,000  |                        |
| <b>Accrued liabilities</b>            |                | 0                      |                | 0                      |                | 0                      |
| <b>Other assets</b>                   | -              |                        | -              |                        | -              |                        |
| <b>Current liabilities</b>            |                | 11,280,000,000         |                | 11,237,000,000         |                | 11,610,000,000         |
| <b>Prepayments and accrued income</b> | -              |                        | -              |                        | -              |                        |
| <b>Non-current liabilities</b>        |                | 28,096,000,000         |                | 30,725,000,000         |                | 35,278,000,000         |
| <b>Different income</b>               |                | -                      |                | -                      |                | -                      |
| <b>Other liabilities</b>              |                | 2,773,000,000          |                | 5,095,000,000          |                | 5,254,000,000          |
| <b>Total assets</b>                   | 62,125,000,000 | 62,125,000,000         | 63,171,000,000 | 63,171,000,000         | 67,952,000,000 | 67,952,000,000         |

## Balance notes

|                            | 2023    | 2022    | 2021    |
|----------------------------|---------|---------|---------|
| <b>Accounting standard</b> | US-GAAP | US-GAAP | US-GAAP |
| <b>Employees</b>           | 18,000  | 17,000  | 14,400  |
| <b>Equity ratio</b>        | 36.48%  | 33.52%  | 30.99%  |
| <b>Debt-equity ratio</b>   | 174.10% | 198.29% | 222.67% |

## Others

|                         | 2023   | 2022   | 2021   |
|-------------------------|--------|--------|--------|
| <b>Tax Expense Rate</b> | 18.18% | 21.47% | 25.09% |

# GILEAD SCIENCES INC.

ISIN: US3755581036 WKN: 375558103 Asset Class: Stock

## Income statement

|   | 2023           | 2022           | 2021           |
|---|----------------|----------------|----------------|
| Turnover  | 27,058,000,000 | 27,085,000,000 | 27,372,000,000 |
| Net income  | 5,664,000,000  | 4,592,000,000  | 6,225,000,000  |
| EBIT  | 6,910,823,500  | 6,279,944,500  | 8,634,109,500  |
| Operating income before taxes                                 | 6,859,000,000  | 5,814,000,000  | 8,278,000,000  |
| Cash Flow   | 8,006,000,000  | 9,072,000,000  | 11,384,000,000 |
| Net interest income   | -568,000,000   | -935,000,000   | -1,001,000,000 |
| Research and development expenses                             | 5,758,000,000  | 4,998,000,000  | 5,363,000,000  |
| Income taxes  | 1,247,000,000  | 1,248,000,000  | 2,077,000,000  |
| Result from investments in subsidiaries, associates and other | 0              | 0              | 0              |
| Revenues per employee   | 1,398,748      | 1,482,505      | 1,768,725      |

## Board of Directors

## Members of Management Board

|                       |                               |
|-----------------------|-------------------------------|
| Jacqueline Barton     | Member of Board of Directors  |
| Jeffrey Bluestone     | Member of Board of Directors  |
| Sandra Horning        | Member of Board of Directors  |
| Ted Love              | Member of Board of Directors  |
| Anthony Welters       | Member of Board of Directors  |
| Harish M. Manwani     | Member of Board of Directors  |
| Javier Rodriguez      | Member of Board of Directors  |
| Kelly Kramer          | Member of Board of Directors  |
| Kevin Lofton          | Member of Board of Directors  |
| Daniel O'Day          | Chairman of Managing Board    |
| Andrew Dickinson      | Member of Executive Committee |
| Deborah H. Telman     | Member of Executive Committee |
| Flavius Martin        | Member of Executive Committee |
| Johanna Mercier       | Member of Executive Committee |
| Jyoti Mehra           | Member of Executive Committee |
| MD, PhD Merdad Parsey | Member of Executive Committee |
| Stacey Ma             | Member of Executive Committee |